Arch Biopartners, Inc. · TSXV:ARCH
Arch Biopartners — Investor Presentation (August 2025)
17 slides from Arch Biopartners's investor presentation, August 2025
Slide 1: Phase II Biotechnology Company Targeting Acute Kidney Injury (AKI)
TSXV: ARCH.V OTCQB: ACHFF.US Phase II Biotechnology Company Targeting Acute Kidney Injury (AKI) August 2025 www.archbiopartners.com
Slide 2: Notes about forward looking statements
Notes about forward looking statements This presentation contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates
Slide 3: Arch is developing new treatments to prevent acute kidney injury (AKI)
Arch is developing new treatments to prevent acute kidney injury (AKI). Advancing LSALT peptide for inflammation-related AKI and repurposing cilastatin for toxin-related AKI. ■ AKI caused by inflammation commonly ■ Each year, AKI affects approximately occurs in patients who have on-pump 14-16 million
Slide 4: Two drugs, two Phase II trials for AKI
Two drugs, two Phase II trials for AKI. LSALT Peptide (ongoing) and cilastatin (pending) are being studied in Phase II trials, each addressing distinct causes of AKI. LSALT Peptide Cilastatin ■ Novel drug candidate for ■ A repurposed drug to prevent inflammation-related AKI. toxin-related AKI. ■ Ongo
Slide 5: LSALT peptide is in an ongoing Phase II trial, targeting CS-AKI
LSALT peptide is in an ongoing Phase II trial, targeting CS-AKI—an unmet medical need. Approximately 30% of cardiac surgery (CS) patients who are on bypass machines experience acute kidney injury (AKI).3,4 ■ There are no approved drug ■ For more information about the treatments for CS-AKI. Phase II
Slide 6: LSALT peptide specifically targets Dipeptidase-1 (DPEP1)
LSALT peptide specifically Read the paper online: targets Dipeptidase-1 (DPEP1). A new mechanism of action. Arch scientists discovered Details of this discovery, that the enzyme DPEP1 including how LSALT peptide mediates the recruitment of targets DPEP1 to block white blood cells and neutrophil adhes
Slide 7: See how LSALT peptide works
See how LSALT peptide works. See how LSALT works in other organs: LSALT peptide was shown to prevent inflammation in Preventing inflammation in preclinical models of AKI, similar to the inflammation the liver. found in CS-AKI. Intravital Kidney Tissue Microscopy Video – CLICK IMAGES TO WATCH THE VIDEOS
Slide 8: Cilastatin is Arch's second drug asset targeting toxin-related AKI
Cilastatin is Arch’s second drug asset targeting toxin-related AKI. 20-30% of AKI cases in hospitalized patients are caused by kidney-toxic drugs.7,8 Cilastatin is being studied to prevent AKI caused by these toxins. Originally developed by Merck for another Arch Biopartners has patents to indicatio
Slide 9: Advancing cilastatin to prevent drug toxin-related acute kidney injury (AKI)
Advancing cilastatin to prevent drug toxin-related acute kidney injury (AKI). Arch is supporting the PONTiAK Phase IIb trial by providing cilastatin drug supply for the study, which is funded and managed by third parties. The PONTiAK trial is an investigator-led Led by researchers in Calgary, the st
Slide 10: Cilastatin as a potential treatment for AKI
Cilastatin as a potential Read the paper online: treatment for AKI. Studies indicate that cilastatin has off-target effects that may help prevent AKI caused by nephrotoxic drugs, including radiographic contrast agents. The PONTiAK trial will evaluate its potential to prevent AKI from other drug toxi
Slide 11: A strong patent position
A strong patent position. LSALT peptide Cilastatin ■ Composition and method of use ■ Method of use patents to patents, including protection for repurpose cilastatin as a treatment off-label applications, issued in the to prevent AKI. United States and PCT countries. ■ There is no commercial history
Slide 12: Next Steps: focused on drug approvals
Next Steps: focused on drug approvals. The CS-AKI and PONTiAK Phase II trials target approximately 50% of AKI cases in hospitalized patients, advancing LSALT peptide and cilastatin as potential game-changers in global kidney care. The CS-AKI Phase II trial supports The Phase IIb PONTiAK trial aims L
Slide 13: Investor Information
Investor Information Latest news highlights, read and subscribe online. Visit our Investor Hub to read the latest news releases July 22, 2025 and download financial reports and filings (also at …start of Patient Recruitment in Phase II SEDAR+). www.archbiopartners.com/investor-hub PONTIAK Trial…to eva
Slide 14: Executive Management
Executive Management Richard Muruve Andrew Bishop Dr. Daniel Muruve MD CEO, Director, Co-founder CFO, Director CSO, Co-Founder Mr. Muruve co-founded the Mr. Bishop is a Partner and A Professor in the Dept. of company with the Arch Co-Founder of Bingley Capital Medicine at the University of Inflammati
Slide 15: A committed board and advisors
A committed board and advisors. Claude Allary, Director Farris Smith, Strategic Advisor Co-founder, partner of Bionest Consulting, CFO, Leo Pharma (North America), Sanofi, Pfizer, Glaxo former CFO of Novo Nordisk Canada. Richard Rossman, Director Patrick Vink, Strategic Advisor Gastroenterologist (ret
Slide 16: Contact us for more information
Contact us for more information. Contact us Latest news releases +1 647 428-7031 office archbiopartners.com/investor-hub/press-releases info@archbiopartners.com X (Twitter) About the company https://x.com/archbiopartners archbiopartners.com/about-us Investor information LinkedIN archbiopartners.com/in
Slide 17: Sources
Sources 1. Sawhney, S., et al. “Harmonization of epidemiology of acute kidney injury and acute kidney disease produces comparable findings across four geographic populations”, Kidney International, Volume 101, Issue 6, 1271 - 1281. https://doi.org/10.1016/j.kint.2022.02.033 2. Pavkov M.E., et al. “Tr
Arch Biopartners — Investor Presentation (August 2025) on 6ix